Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.06), $0.04 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Gartner places F5 in AI application security emerging market report
• TotalEnergies strikes $1.8B deal with GIP on African assets